Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
tolvaptan
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:European_Medicines_Agency
|
| gptkbp:ATCCode |
C03XA01
|
| gptkbp:brand |
tolvaptan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Jinarc
|
| gptkbp:manufacturer |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:mechanismOfAction |
vasopressin V2 receptor antagonist
|
| gptkbp:sideEffect |
thirst
liver injury polyuria |
| gptkbp:usedFor |
gptkb:autosomal_dominant_polycystic_kidney_disease
|
| gptkbp:bfsParent |
gptkb:Otsuka_Pharmaceutical_Co.
|
| gptkbp:bfsLayer |
6
|